March 26, 2010

Dangers Of Local Anesthetic Pain Pumps After Surgery

The Pain Pump Law Blog has posted an article about problems associated with the use of local anesthetic pain pumps after surgery.

In 2004, the FDA published an article that summarized 40 injuries that were reported due to pain pump use after surgery. The injuries consisted of things like wound infection, tissue necrosis and cellulitis. "45% of the surgeries were orthopedic, typically total knee replacements. 20% were for podiatric surgeries, including bunionectomies, plantar fasciotiomies, and others."

The local anesthetic Bupivacaine, also called Marcaine, was used in all injury cases.

The consequences of these adverse events were typically severe and required intervention and additional medical and surgical treatment. The authors’ review of the literature found little had been written to support a causal link between pain pumps and the complications that had been reported to the FDA. Therefore, the authors’ conclusion was tentative and stated the reports may represent sentinel events, i.e., an early warning that is representative of a widespread problem, or alternatively, these may be isolated incidents.

Before pain pumps were commonly used, local anesthetics were administered in small doses and harm to tissue was more rare because "cells damaged by local anesthetics typically regenerate and surgical pain and dressings may have masked such harm." But pain pumps put in a much higher concentration and dosage of medication, thus magnifying the possibility of tissue damage.


September 29, 2009

Lawsuits over Dangers of Yaz and Yasmin

The Utah Personal Injury Law Firm Blog has posted an article about the dangers of the birth control pills Yaz and Yasmin. The pills are basically identical and have been marketed without enough warnings about their dangerous, and potentially deadly, side effects.

Both drugs contain drospirenone, which can be dangerous when taken daily.

Drospirenone can cause severe heart problems by increasing blood potassium levels. Patients have also suffered from strokes, cardiac arrhythmias, and gallbladder disease. Some women have even died from health problems resulting from Yaz and Yasmin.

Several lawsuits have been filed against Bayer, the maker of the drug, for failing to give adequate warnings and for "misleading the public." The lawsuits are trying to hold Bayer responsible for not doing enough research and testing prior to making it available to the public. The lawsuits also include

failing to recall the drug once it became apparent that it was dangerous, and for vehemently marketing the drug without properly warning of potential side effects.

September 15, 2009

Weight Loss Drug's Possible Link to Liver Damage

http://www.alabamaproductinjurylawyer.com/2009/08/fda_probes_orlistat_alli_and_x.htmlThe Alabama Product Injury Lawyer Blog has posted an entry about a new drug warning from the FDA. The FDA has issued an "early communication" warning for weight loss drugs containing Orlistat. So far, the agency says it has received 32 reports of "serious liver injury," including 6 instances of complete liver failure in patients who had taken the drug. Orlistat is in the over the counter weight loss drug Alli and the prescription drug Xenical.

GlaxoSmithKline, which manufactures Alli, the OTC version of this drug, insists "there is no evidence that Alli causes liver damage". The company went on to indicate the people who are overweight or obese are predisposed to liver problems.

The FDA released a statement saying that there is no "definite association" between Orlistat and liver injury, but the data is being reviewed.

September 13, 2009

Antidepressants Increase Risk of Suicidal Thoughts in Patients Under 25

The Alabama Product Injury Lawyer Blog has posted an article about a study done by the FDA confirming that people under age 25 who take an antidepressant are more likely to have suicidal tendencies and thoughts than older people on the same medication.

A warning about the increased tendencies has been present on antidepressant medications since 2005. Psychiatrists have complained that the "black box" warning scared people away from taking the type of medication and have even suggested that the FDA remove the warning...

based on the significant decline in people seeking treatment for depression. However, this recent study by the FDA, which looked at 372 clinical trials from eight different drug makers involving over 100,000 individuals, confirmed the increase risk of suicide in those under 25 taking these type of medications

This article suggests that the warnings really are necessary.

Before the black box warnings were imposed by the FDA in 2005, primary care physicians were prescribing this type of medication to children and young adults going through what can only be described as "teenage angst". There typically was no diagnosis of depression, much less any formal testing to address whether the young adult or child was indeed depressed. Several weeks later, these young, vibrant souls, with many promising years ahead, were found dead as a result of self inflicted injury.

May 3, 2009

"Supreme court sends message regarding drug lawsuits"

Michael E. Grossman's Personal Injury Blog, has posted an article about a Vermont woman's lawsuit over side effects from a drug.

In 2000, she received a shot of the migraine medicine Phenergan and contracted gangrene shortly thereafter. The medicine's FDA warning label didn't list gangrene being a possible side effect.

The woman's attorney filed a suit against Wyeth, makers of the medicine, stating that "the company was responsible for meeting The State of Vermont's own drug warning label laws." She was awarded $6.7 million from a jury.

Wyeth's attorneys appealed the decision taking it to the Supreme Court. In a 6-3 decision, the Supreme Court upheld the verdict sending a strong message regarding the power of state liability laws. Prior to this significant outcome, many held to the belief that state liability laws were overridden by the FDA's standards. If a drug's warning label met the federal requirements, an opposing or differing law at the state level was thought to be less relevant. The outcome will likely prompt many pending drug injury cases to move forward where a potential roadblock once kept such cases at a stand still.
March 17, 2009

Drug Linked to Brain Infection

The Alabama Product Injury Lawyer Blog posted an article discussing the correlation between the drug Raptiva and a rare brain infection. The infection, progressive multifocal leukoencephalopathy... or PML for short, has occurred in 3 patients who were taking Raptiva for cases of plaque psoriasis that varied in severity.

In October 2008,the FDA issued a black box warning for the drug, asserting that it was related to several life-threatening illnesses. The European Medicines Agency intends to pull the drug from the market, stating "the risks outweigh the benefits."

March 15, 2009

Drug Company Hid Bad Studies

The Alabama Product Injury Lawyer Blog posted an article, originally from Bloomberg.com, about the drug manufacturer AstraZeneca. Craig P. Niedenthal says that the company, which manufactures the medication Seroquel (an anti-psychotic drug), has agreed to make documents available to the public which discuss unfavorable results from the drug during the clinical testing period.

Jef Feeley and Margaret Cronin Fisk, writers of the article, cite that more than 150,00 people have sued AstraZeneca for withholding "information of a connection between diabetes and Seroquel use from doctors and patients. Many of the lawsuits also claim AstraZeneca promoted Seroquel, approved by the U.S. Food and Drug Administration for schizophrenia and bipolar disorder, for unapproved uses."

AstraZeneca, prompted by the same court hearing, also agreed to include a warning on the label that will inform the consumer of the link between diabetes and this medication.

December 25, 2008

Drug Maker Wyeth Writing Medical Journal Articles About Questionable Drugs?

Check out this short and to the point article about the drug giant Wyeth paying to ghost write medical journal articles about drugs under litigation. Amazing but I guess not surprising.... Thanks to Mark Zamora of "A Georgia Lawyer" blog for spotting this.

November 29, 2008

Ties To Big Pharma Companies - Does It Influence Journalists?

Our friend Craig P. Niedenthal has an excellent (but disturbing) post related to the recent revelation that Dr. Frederick K. Goodwin (who hosts a program on NPR) has financial ties to "Big Pharma" and the possible effects this may have on his opinions related to the safety of certain drugs.

Read the entire post but here is an excerpt:

The Times reports that between 2000 and 2007 Dr. Goodwin received at least $1.3 million for marketing lectures he gave for several drug manufacturers. This income has not been previously disclosed on the program.
In March of this year, Dr. Goodwin had a show in which he took the position that there was no credible scientific evidence linking anti-depressants and violent or suicidal behavior. The Times reports that that same week Dr. Goodwin earned approximately $20,000 lecturing on behalf of GlaxoSmithKline who manufacturers Paxil, an SSRI. GlaxoSmithKline, the Times indicates, has suppressed studies for years that indicate that Paxil increased suicidal behavior and ideation.

If you have questions about your legal options related to defective drugs, please feel free to contact us through this blog or by calling us at 205-879-2447 for a free consultation.

July 3, 2008

Great News For Alabama - Verdict Against GlaxoSmithKline And Novartis For Overcharging Alabama

On Tuesday a jury returned a verdict in Montgomery, Alabama, in favor of the State of Alabama against GlaxoSmithKline and Novartis for $114 million. Read more of this fascinating story at the Beasley Allen website here.

Here are some more articles about this verdict that the Beasley firm obtained on behalf of Alabama - a news conference is set for today and the Attorney General has issued a press release about this verdict.

April 12, 2008

A Dangerous Drug? Or Just A Stupid Warning?

One of the funniest blogs around is Legal Juice and this recent post is a classic on the drug Xyzal. You have to read this for yourself. I don't know what to say.

March 18, 2008

Diabetes Drug Avandia May Be Linked to Heart Attacks

Alabama residents and consumers should be aware of the recent studies linking Avandia to heart attacks. Republican Senator Charles Grassley stated last year on the senate floor that Avandia may be linked to more than 100,000 heart attacks. There are several articles out discussing this issue including, "Diabetes Drug Avandia: Heart Risk?" on the MediceNet.com website and a Foxnews.com story, "Study: Avandia Raises Risk of Heart Attack."

Avandia is a drug developed by GlaxoSmithKline and used to treat Type 2 diabetes. The drug was approved in 1999 by the FDA to help reduce blood-sugar levels in people with type 2 diabetes. However, shortly after its release, one researcher, Bruce M. Psaty, MD, PhD criticized the drug noting that there was little evidence to support use of the drug.

While GlaxoSmithKline strongly denies the report and says that further study needs to be done, the short term study performed by Dr. Steven Nissen and Kathy Wolski, MPH, indicated "that Avandia increases heart attack risk by 43%-- and increases risk of death from heart disease by 64%."

If you have taken this drug and suffered a heart attack or any other cardiovascular problems, there may be a link. You should contact an attorney to evaluate your claim.

March 1, 2008

Blood Thinner Heparin Linked To Numerous Deaths

On the heels of the story about the drug Traysol, here is another story about a drug - this time the very well known and used blood thinner Heparin. According to this story by cbsnews.com, the FDA is investigating the drug and its connections to potentially contaminated ingredients from China.

The introduction to this short, but excellent news article is as follows:


Every day thousands of Americans rely on the blood thinner Heparin to survive.

Now that drug is under suspicion for 21 deaths and hundreds of allergic reactions. Baxter International, a major manufacturer of the drug, has stopped selling almost all forms of Heparin.

CBS News medical correspondent Dr. Emily Senay reports that officials say they have not yet identified the cause, but are looking to China where nearly half of Heparin's raw ingredients come from

Read the rest of this story here and stay tuned for more developments on this troubling issue.

March 1, 2008

The Danger of the Drug Trasylol - Linked To Many Deaths

Brian Beckcom from the excellent Houston Injury & Accident Law blog recently posted an article about how the drug Traysylol has been linked to a staggering number of deaths. As many as 1000 per month. You can read the story from 60 Minutes here at cbsnews.com but here is the chilling introduction:

This is the story of a drug that was on the market for 14 years and may have contributed to the deaths of thousands of patients. Trasylol, made by Bayer, is given in the operating room to control bleeding. It was a big money maker.

As correspondent Scott Pelley reports, Bayer marketed Trasylol aggressively until it was used in about one third of all cardiac bypass operations in America.

But then, in 2006, a study showed widespread death associated with Trasylol, and as it turns out there was concern long before that.

How much did Bayer know? And why did it take Bayer and the U.S. Food and Drug Administration nearly two years to take the drug off the market after major studies revealed the danger? Two years - during which it's estimated Trasylol was contributing to the loss of one thousand lives a month.

Please read the rest of this story and if you have been injured or had a loved one die as a result of using Trasylol please contact an attorney who is experienced in dealing with dangerous drugs - our firm and all others that we know about do not charge to discuss your options with you.

February 24, 2008

Alabama Jury Returns Verdict Against a Drug Company

Congratulations to the Beasley Allen firm for its verdict on Thursday, February 22 against AstraZeneca PLC. This was a difficult and hard fought case that is far from over.

The Beasley firm represented the State of Alabama claiming that the drug company had over-charged the State's medicaid system for drugs. Through the trial process, they discovered that the drug company had been charging medicaid one fee and then selling the drugs to wholesalers for much less money.

After hearing all of the evidence, the jury returned a verdict against AstraZeneca PLC for a total of $215 million, $40 million in compensatory damages and $175 million in punitive damage. The drug company vehemently denies any wrongdoing and plans on appealing.

To read more about read the story at several different cites including, here, here or here.

This was an important win for the State and several other states, as there is another trial scheduled in April under the same theory, but against another drug manufacturer. Additionally, other states are looking at bringing similar type suits. We wish them luck.